Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics.
Read more about cookies

Britt Vervoort

Genetic aberrations affecting the B lymphoid transcription factor IKZF1 occur in about 15% of pediatric ALL patients and are associated with increased relapse risk. Therefore, more effective treatment strategies for this patient group are needed. In this project we aim to understand the molecular mechanisms driving therapy resistance in patients harboring IKZF1 deletions. Moreover, we try to find novel drug targets to sensitize resistant cells and increase the drug response to commonly used therapeutic agents.